AusperBio

aid: ausperbio
name: AusperBio
description: 'AusperBio — AusperBio Therapeutics, Inc. in the United States and Ausper Biopharma Co., Ltd. (杭州浩博医药有限公司) in
  Hangzhou, China — is a clinical-stage biopharmaceutical company founded in 2019 that develops oligonucleotide and targeted
  delivery technologies, with an initial focus on achieving a functional cure for chronic hepatitis B infection. Its proprietary
  Med-Oligo antisense oligonucleotide (ASO) platform pairs novel ASO design and optimization with targeted delivery conjugation
  chemistry, and its Au-HALO hepatocyte-targeting delivery technology extends the same modular approach to siRNA. The lead
  candidate AHB-137 is an unconjugated ASO that completed enrollment in two Phase II trials and received China CDE clearance
  to enter Phase III; a second clinical candidate, AHB-171, is a hepatocyte-targeted siRNA. The company has raised more than
  $200M across Series B, B+ and B2 rounds from investors including Qiming Venture Partners, HanKang Capital, CDH Investments,
  Sherpa Capital, YuanBio Venture Capital and Genesis Capital. AusperBio sells therapeutics, not software: it publishes no
  developer program, no public API, no SDK and no machine-readable API contract. Its only machine-readable surface is the
  private Spring Boot CMS backend that renders ausperbio.com, whose springdoc API description is correctly locked behind authentication.'
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://www.ausperbio.com/favicon.ico
url: https://raw.githubusercontent.com/api-evangelist/ausperbio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: no-api-surface
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Biopharmaceutical
- Life Sciences
- Therapeutics
- Oligonucleotide
- Antisense Oligonucleotide
- siRNA
- Clinical Trials
- Hepatitis B
- Drug Development
- Health
- China
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/ausperbio-domain-security.yml
- type: Website
  url: https://www.ausperbio.com/
- type: About
  url: https://www.ausperbio.com/company.html
- type: Team
  url: https://www.ausperbio.com/leadership.html
- type: Product
  url: https://www.ausperbio.com/platform.html
  description: Med-Oligo ASO platform and Au-HALO targeted delivery technology.
- type: Research
  url: https://www.ausperbio.com/pipeline.html
  description: Clinical pipeline — AHB-137 (ASO) and AHB-171 (siRNA) for chronic hepatitis B.
- type: Blog
  url: https://www.ausperbio.com/news.html
- type: News
  url: https://www.ausperbio.com/news.html
- type: Support
  url: https://www.ausperbio.com/contact-us.html
- type: Contact
  url: https://www.ausperbio.com/contact-us.html
- type: Careers
  url: https://www.ausperbio.com/careers.html
- type: TermsOfService
  url: https://www.ausperbio.com/term.html
- type: PrivacyPolicy
  url: https://www.ausperbio.com/privacy.html
- type: LinkedIn
  url: https://www.linkedin.com/company/ausperbio
- type: LLMsTxt
  url: llms/ausperbio-llms.txt
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: AusperBio develops antisense-oligonucleotide and siRNA drugs for chronic hepatitis B, so there is no software product
    to expose; ausperbio.com is a Vue single-page app that returns an identical 2,601-byte shell (md5 519d85ce…) for every
    path including invented ones, and the only machine-readable API description on the estate is the springdoc description
    of the private Spring Boot CMS at cms.ausperbio.com/jzy-admin/, which is correctly 401-gated and is site infrastructure
    rather than a product surface.
  evidence:
  - url: https://www.ausperbio.com/openapi.json
    status: 200
    note: Soft 404 — byte-identical to the SPA shell returned for a nonexistent control path.
  - url: https://www.ausperbio.com/definitely-not-a-real-path-zzz999
    status: 200
    note: Control path proving every 200 on this host is the SPA catch-all.
  - url: https://www.ausperbio.com/llms.txt
    status: 200
    note: Soft 404 — SPA shell, not an llms.txt.
  - url: https://www.ausperbio.com/.well-known/agent-card.json
    status: 200
    note: Soft 404 — SPA shell, not an agent card. No A2A card published.
  - url: https://cms.ausperbio.com/jzy-admin/v3/api-docs
    status: 200
    note: Returns {"code":401,"msg":""} — springdoc API description exists but is authentication-gated.
  - url: https://cms.ausperbio.com/jzy-admin/doc.html
    status: 401
  - url: https://api.ausperbio.com/
    status: 0
    note: No such host in DNS. Same for developer. and docs. subdomains.
  checked: '2026-08-06'